Seattle Genetics has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Genentech. The milestone was triggered by Genentech’s submission of an IND application with the FDA for an ADC utilizing Seattle Genetics’ technology for the treatment of cancer. “This IND submission is reflective of the continued progress by our collaborators in the development of product candidates based on our proprietary ADC technology,” said Eric L. Dobmeier, chief business officer of Sea...